OverviewSuggest Edit

Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. The Company develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities. 

TypePublic
Founded2006
HQNew York, NY, US
Websitefortressbiotech.com
Overall CultureC+

Latest Updates

Employees (est.) (Dec 2019)93(+6%)
Job Openings1
Revenue (FY, 2020)$45.6 M(+25%)
Share Price (Jun 2021)$3.9(+2%)
Cybersecurity ratingAMore

Key People/Management at Fortress Biotech

Lindsay A. Rosenwald

Lindsay A. Rosenwald

Chairman, President and Chief Executive Officer
Michael S. Weiss

Michael S. Weiss

Executive Vice Chairman, Strategic Development
George Avgerinos

George Avgerinos

Senior Vice President, Biologics Operations
Eric K. Rowinsky

Eric K. Rowinsky

Co-Vice Chairman and Director
Jimmie Harvey

Jimmie Harvey

Director
Malcolm Hoenlein

Malcolm Hoenlein

Director
Show more

Fortress Biotech Office Locations

Fortress Biotech has offices in New York and Waltham
New York, NY, US (HQ)
2 Gansevoort St
Waltham, MA, US
95 Sawyer Rd #110
Show all (2)

Fortress Biotech Financials and Metrics

Fortress Biotech Revenue

Embed Graph
View revenue for all periods
Fortress Biotech's revenue was reported to be $45.6 m in FY, 2020
USD

Revenue (Q1, 2021)

11.6m

Gross profit (Q1, 2021)

7.7m

Gross profit margin (Q1, 2021), %

66.3%

Net income (Q1, 2021)

(26.1m)

EBIT (Q1, 2021)

(30.0m)

Market capitalization (4-Jun-2021)

383.2m

Closing stock price (4-Jun-2021)

3.9

Cash (31-Mar-2021)

289.9m

EV

185.7m
Fortress Biotech's current market capitalization is $383.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

187.6m26.9m36.6m45.6m

Revenue growth, %

(86%)36%

Cost of goods sold

3.7m6.1m10.5m14.6m

Gross profit

183.9m20.8m26.1m31.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

44.7m50.7m46.9m55.4m63.8m63.7m6.5m9.3m9.8m12.9m9.5m11.6m

Cost of goods sold

469.0k878.0k505.0k1.5m1.7m1.9m2.4m2.7m3.8m3.1m3.9m

Gross profit

44.2m49.8m46.4m54.0m62.2m4.6m6.9m7.1m9.1m6.3m7.7m

Gross profit Margin, %

99%98%99%97%97%71%74%72%71%67%66%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

113.9m65.5m136.9m233.4m

Accounts Receivable

7.8m5.5m13.5m19.3m

Prepaid Expenses

12.7m6.7m4.1m6.7m

Inventories

171.0k678.0k857.0k1.4m
Quarterly
USDQ2, 2013Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

67.9m134.0m144.3m110.5m124.0m98.6m95.9m116.4m149.4m134.9m135.9m183.3m289.9m

Accounts Receivable

1.4m3.3m5.6m8.3m5.3m5.4m8.0m3.1m5.1m15.8m11.2m19.4m

Prepaid Expenses

243.0k8.5m11.9m10.7m14.3m13.9m14.1m4.3m3.4m4.1m4.5m3.2m5.5m

Inventories

204.0k299.0k318.0k222.0k299.0k674.0k629.0k732.0k941.0k769.0k1.2m2.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(99.8m)(141.9m)(101.7m)(103.0m)

Depreciation and Amortization

2.8m1.4m1.9m3.7m

Inventories

32.0k(507.0k)(179.0k)(547.0k)

Accounts Payable

9.7m4.7m2.1m6.5m
USDQ2, 2013

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.4 x
Show all financial metrics

Fortress Biotech Revenue Breakdown

Embed Graph

Fortress Biotech revenue breakdown by business segment: 18.7% from Other Branded, 76.6% from Targadox and 4.7% from Other

Fortress Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Fortress Biotech Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Fortress Biotech Online and Social Media Presence

Embed Graph

Fortress Biotech Company Culture

  • Overall Culture

    C+

    74/100

  • CEO Rating

    A+

    100/100

  • Compensation

    F

    43/100

Learn more on Comparably

Fortress Biotech News and Updates

Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced t…

Fortress Biotech Announces Webinar Hosted by ROTH Capital Partners Featuring Partner Company Journey Medical Corporation

NEW YORK and SCOTTSDALE, Ariz., May 19, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effective…

REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure

Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced …

Thinking about buying stock in Jaguar Health, Funko, ChargePoint Holdings, Fortress Biotech, or Lordstown Motors?

NEW YORK, April 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, FNKO, CHPT, FBIO, and RIDE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Fortress Biotech Blogs

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy i…

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

 Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis -- Phase 3 studies of CAEL-101 in AL amyloidosis are underway - BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)-- Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that…

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial WORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical br…

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2021, and recent corporate highlights. James F. Oliviero, P…

Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights

Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019 Our partner company, Cyprium Therapeutics, and Sentynl Therapeutics, a wholly-owned subsidiary of the Zydus Group, signed a Development and Asset Purchase Agreement for CUTX-101 for the treatment of Menkes …

Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

WORCESTER, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic …
Show more

Fortress Biotech Frequently Asked Questions

  • When was Fortress Biotech founded?

    Fortress Biotech was founded in 2006.

  • Who are Fortress Biotech key executives?

    Fortress Biotech's key executives are Lindsay A. Rosenwald, Michael S. Weiss and George Avgerinos.

  • How many employees does Fortress Biotech have?

    Fortress Biotech has 93 employees.

  • What is Fortress Biotech revenue?

    Latest Fortress Biotech annual revenue is $45.6 m.

  • What is Fortress Biotech revenue per employee?

    Latest Fortress Biotech revenue per employee is $490.3 k.

  • Who are Fortress Biotech competitors?

    Competitors of Fortress Biotech include Seed Health, Brooks Life Sciences and Bioiberica.

  • Where is Fortress Biotech headquarters?

    Fortress Biotech headquarters is located at 2 Gansevoort St, New York.

  • Where are Fortress Biotech offices?

    Fortress Biotech has offices in New York and Waltham.

  • How many offices does Fortress Biotech have?

    Fortress Biotech has 2 offices.